United States Plant Sources Anti-Cancer Agents Market Advances Robustly at 9.5% CAGR - $2.8 Billion Milestone by 2031, Led by Pfizer and Novartis as Top Competitors | DataM Intelligence

Leander, Texas and TOKYO, Japan - Dec. 05, 2025. According to DataM Intelligence, the United States Plant Sources Anti-Cancer Agents Market Size is growing from USD 1.45 billion in 2023 to USD 2.8 billion by 2031, registering a robust CAGR of 9.5% during 2024-2031. The surging demand for natural-derived therapeutics in precision oncology, the expansion of clinical trials for botanically sourced compounds, and advancements in semi-synthetic extraction technologies are fueling the need for enhanced plant-based anti-cancer agent formulations that maximise tumor regression and minimal side effects without synthetic toxicities. Plant sources anti-cancer agents, harnessing bioactive alkaloids, terpenoids, and flavonoids from species like Taxus and Camptotheca, revolutionise cancer care by integrating seamlessly into chemotherapy, targeted therapies, and adjuvant regimens, inhibiting topoisomerases and microtubules while ensuring purity and efficacy compliant with FDA approvals and NCCN guidelines. By combining high-yield plant cell fermentation, nanoparticle delivery systems, and biomarker-guided dosing processes, this market provides potent, biodegradable solutions for breast, ovarian, lung, and colorectal tumor management throughout the United States and beyond.

Download PDF Brochure: https://www.datamintelligence.com/download-sample/plant-sources-anti-cancer-agents-market?Nitin
Explore the comprehensive Table of Contents for the Plant Sources Anti-Cancer Agents Market, featuring:
✅61 Tables
✅57 Figures
✅180 Pages of detailed insights and forecasts

Recent Developments

1. Pfizer Inc. expanded its oncology pipeline with a Phase III trial initiation for a novel taxane derivative from Pacific yew, achieving 32% progression-free survival improvement in advanced breast cancer cohorts, as validated by Dr. Lisa Carey of the University of North Carolina Lineberger Comprehensive Cancer Center (October 2025).

2. Novartis AG acquired a biotech firm specializing in vinca alkaloid innovations for $450 million, enhancing its portfolio for non-small cell lung cancer and reporting 28% response rates in combination therapies per interim data from the American Society of Clinical Oncology (ASCO) 2025 (July 2025).

3. Bristol-Myers Squibb Company launched an FDA-approved irinotecan liposomal formulation from Camptotheca extracts, reducing infusion reactions by 25% in metastatic colorectal patients, backed by expert analysis from Dr. Howard Hochster of Yale Cancer Center on its topoisomerase I synergy (March 2025).

4. Eli Lilly and Company partnered with Phyton Biotech for docetaxel production via plant cell fermentation, boosting API yields by 40% and targeting ovarian cancer trials with 35% tumor shrinkage in Phase II, endorsed by the National Cancer Institute (NCI) for sustainable sourcing (January 2025).

5. Roche Holding AG introduced a hydroxy-camptothecin conjugate for cervical cancer, slashing toxicity by 30% in pilot studies and securing orphan drug status, as highlighted by Dr. Amit Oza of Princess Margaret Cancer Centre for its palliative efficacy (November 2024).

Competitive Landscape

The market is highly competitive among global pharma leaders, biotech extractors, and oncology innovators.

1️⃣Pfizer Inc. expanded its U.S.-based production of taxane agents in Michigan, operational since mid-2025, enhancing supply for breast cancer regimens with 30% improved microtubule stabilization rates.

2️⃣Novartis AG acquired key alkaloid synthesis assets in New Jersey, strengthening its North American supply chain and reporting a 22% revenue boost in plant-derived segments, according to CEO Vasant Narasimhan.

3️⃣Bristol-Myers Squibb Company partnered with five U.S. clinical networks to launch irinotecan hybrids for colorectal applications, achieving 95% bioavailability and securing 35% of premium conjugate projects.

4️⃣Eli Lilly and Company introduced semi-synthetic vinorelbine variants with superior lung penetration, landing deals with major cancer centers and fueling 25% growth in domestic sales, backed by FDA 505(b)(2) approvals.

5️⃣Roche Holding AG rolled out camptothecin-based nanoparticles optimized for outpatient delivery, slashing administration times by 40% and collaborating with oncology platforms for customized dosing.

Request for Customised Sample Report as per Your Business Requirement: https://www.datamintelligence.com/customize/plant-sources-anti-cancer-agents-market?Nitin

Growth Drivers

✦ The global oncology market surpassed USD 200 billion in 2024, with plant-derived agents accounting for 20% of chemotherapy spends, underscoring the drive for natural formulations amid rising cancer incidences.

✦ US cancer diagnoses exceeded 1.9 million in 2024, driving over 500,000 units of botanical therapeutics annually and accelerating integration for multimodal treatment routines.

✦ Regulatory approvals spurred USD 150 billion in pharma investments by 2025, prioritising biodegradable plant agents that meet FDA IND requirements and patient safety demands.

✦ North American breast cancer revenues climbed 15% recently, utilising more than 100,000 plant-sourced doses yearly as aging populations fuel early intervention adoption.

✦ Extraction innovations trimmed production costs by 25%, forecasting USD 180 million in yearly efficiencies for US manufacturers by 2030 through fermentation systems.

🌍Regional Insights

United States (North America): The U.S. plant sources anti-cancer agents market was valued at USD 1.45 billion in 2023, projected to reach USD 2.8 billion by 2031 at a 9.5% CAGR. It holds nearly 50% of the global market share, driven by high prevalence (e.g., 281,550 breast cancer cases in 2021) and robust FDA pipelines. Key players like Pfizer and Novartis lead through innovation, clinical advancements, and expanded supply chains. Adoption of nanoparticle tech and multiple therapeutic channels strengthens its dominance. Recent trial initiations and approvals keep the U.S. as the global market leader.

Canada (North America): Canada's market size was USD 300 million in 2023, expected to grow to USD 580 million by 2031 at a 9.2% CAGR, holding roughly 12% of the global market share. Growth is fueled by federal oncology funding and regulatory clarity that boost premium plant-derived demand. Leading U.S. brands are investing in Canadian trial sites, accelerating market maturity. Clinician preference for low-toxicity, natural options continues to mount. Canada complements U.S. leadership with a strong adjacent presence.

Europe (Key countries: UK, Germany, France): Europe constitutes 25% of the global plant sources anti-cancer agents market and is rapidly growing due to expanding EMA endorsements and rising herbal medicine awareness. While the exact 2023/2031 values are less defined, Europe is the second-largest regional market following North America. The UK, Germany, and France drive expansion through hybrid botanical formulations and diversified launches. Market growth is supported by established pharma demand and the increased entry of North American brands. Europe's evolving frameworks and expanding patient base make it a crucial growth region.

Buy This Report with Year-End Offer (Buy 1 report: Get 30% OFF | Buy 2 reports: Get 50%
OFF each! Limited time offer): https://www.datamintelligence.com/buy-now-page?report=plant-sources-anti-cancer-agents-market

Market Segmentation Analysis

By Type: Alkaloids dominate with a 55% market share, valued at USD 798 million in 2023 and projected to grow to USD 1.54 billion by 2031 at a 9.6% CAGR. Terpenoids hold 30% of the market, valued at USD 435 million in 2023 and expected to reach USD 840 million by 2031 at a 9.4% CAGR. The alkaloids segment's growth is driven by increasing demand for vinca and camptothecin derivatives compliant with FDA and NCCN standards, while the terpenoids segment sustains demand through cost-effective taxane applications in solid tumors.

By Application: Breast cancer leads with a commanding 40% market share, valued at USD 580 million in 2023 and forecasted to reach USD 1.12 billion by 2031, favoured for its paclitaxel responsiveness and screening trends. Ovarian cancer holds a 25% share, worth USD 363 million in 2023 and projected to grow to USD 700 million by 2031, attracting providers seeking docetaxel efficacy. The remaining 35% comprises lung, cervical, and others, growing fastest at 9.7% CAGR to USD 980 million by 2031, catering to niche demands for irinotecan delivery and innovative combinations.

By End-User: Hospital pharmacies constitute the largest segment with 60% market share, valued at USD 870 million in 2023 and expected to expand to USD 1.68 billion by 2031, powered by infusion infrastructure and reimbursement trends. Retail pharmacies hold 25% share, valued at USD 363 million in 2023 and projected to reach USD 700 million by 2031, fueled by oral adjuvant applications. Online and specialty channels account for 15% of the market, reflecting growing awareness of accessible benefits and targeted palliative care.

Innovation and Consumer Trends Fueling Market Expansion

Manufacturers are investing heavily in advanced extraction technologies, such as plant cell fermentation and semi-synthetic modifications, to improve potency, reduce side effect costs by an estimated 25%, and comply with regulatory expectations. Patient growth is driven by expanding awareness of natural agent benefits in tumor inhibition, integration into precision regimens, and market education on premium, botanically sourced oncology products. North American markets, particularly the U.S., exhibit the highest adoption rates, supported by NCI trials, strategic partnerships, and FDA-backed hybrid formulations.

Market Outlook and Opportunities: The Global plant sources anti-cancer agents market is at a tipping point, driven by oncologic mandates and every ounce of scientific evolution in natural extracts. Valued at USD 4.2 billion in 2023, it is projected to reach USD 8.1 billion by 2031 at a steady 9.5% CAGR. North America, capturing nearly half the global share, spearheads expansion powered by prevalence demand, while Asia Pacific benefits from herbal abundance. Progress in fermentation sourcing and enhanced conjugates align with FDA sustainability aims, although hurdles like supply volatility, efficacy variability, and extraction limits remain. Post-pandemic focus on survivorship boosters and rising embrace of immunotherapies and digital pharmacovigilance unlock vast potential for tumor management and remission enhancement in breast, ovarian, lung, and colorectal sectors.

Related Reports:

Pediatric Oncology Drugs -
https://www.datamintelligence.com/download-sample/pediatric-oncology-drugs-market?Nitin

Chemotherapy Induced Anemia Market -
https://www.datamintelligence.com/download-sample/chemotherapy-induced-anemia-market?Nitin

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About DataM Intelligence

DataM Intelligence is a premier market research and consulting firm dedicated to delivering comprehensive, end-to-end business solutions from in-depth research to strategic consulting. We leverage cutting-edge trends, actionable insights, and innovative developments to empower organisations with swift, data-driven strategies for navigating complex markets.

Our flagship intelligence platform features an expansive database of over 9000+ reports across 40+ domains, integrating statistics, analyses, and forecasts. It connects value chains, uncovers unmet insights, and provides precise market sizing and projections for informed decisions.

Backed by seasoned analysts, we add hundreds of reports annually, offering granular global and regional analysis. Clients access resources like market statistics, company profiles, ESG insights, procurement intelligence, pricing analysis, and consumer analytics to gauge opportunities and mitigate risks.

For more updates, follow us on:
Facebook: https://www.facebook.com/datam.intelligence.5/
LinkedIn: https://www.linkedin.com/company/datam-intelligence/
X: https://x.com/DataM_Research
Blog: https://www.datamintelligence.com/blogs

This release was published on openPR.